Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) EBT (2016 - 2025)

Historic EBT for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$16.9 million.

  • Northwest Biotherapeutics' EBT fell 35.54% to -$16.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$73.4 million, marking a year-over-year decrease of 541.68%. This contributed to the annual value of -$74.3 million for FY2024, which is 2226.54% down from last year.
  • Northwest Biotherapeutics' EBT amounted to -$16.9 million in Q3 2025, which was down 35.54% from -$16.6 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' EBT registered a high of -$11.7 million during Q3 2021, and its lowest value of -$22.5 million during Q2 2022.
  • Moreover, its 5-year median value for EBT was -$16.9 million (2024), whereas its average is -$16.8 million.
  • Examining YoY changes over the last 5 years, Northwest Biotherapeutics' EBT showed a top increase of 7818.48% in 2021 and a maximum decrease of 14848.66% in 2021.
  • Over the past 5 years, Northwest Biotherapeutics' EBT (Quarter) stood at -$11.8 million in 2021, then crashed by 64.0% to -$19.4 million in 2022, then grew by 15.54% to -$16.4 million in 2023, then decreased by 28.09% to -$21.0 million in 2024, then rose by 19.28% to -$16.9 million in 2025.
  • Its last three reported values are -$16.9 million in Q3 2025, -$16.6 million for Q2 2025, and -$18.9 million during Q1 2025.